Want to see CAPR full AI Analyst Report?
CAPR Stock Chart & Stats
$34.70
-$0.36(-2.53%)
At close: 4:00 PM EST
$34.70
-$0.36(-2.53%)
Day’s Range― - ―
52-Week Range$4.30 - $40.37
Previous CloseN/A
Volume187.65K
Average Volume (3M)1.45M
Market Cap
$1.13B
Enterprise Value$1.49K
Total Cash (Recent Filing)$278.61M
Total Debt (Recent Filing)$21.12M
Price to Earnings (P/E)―
Beta2.29
Next Earnings
Aug 12, 2026EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.32
Shares Outstanding57,911,892
10 Day Avg. Volume1,264,643
30 Day Avg. Volume1,450,641
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)4.39
Price to Sales (P/S)0.00
P/FCF Ratio-18.45
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$53.00Price Target Upside52.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.4
Revenue Forecast (FY)$131.21M
Bulls Say, Bears Say
Bulls Say
Pivotal Phase 3 EfficacyStatistically significant Phase 3 efficacy in a 106-patient pivotal trial materially strengthens the clinical foundation for approval and adoption. Durable benefit on primary and controlled secondary endpoints supports label argumentation, physician uptake, and payer discussions over the next several quarters.
Regulatory Progress With Clear TimelineAn accepted BLA and confirmed PDUFA date materially reduce regulatory timeline uncertainty and allow focused commercialization planning. This structural clarity enables staged manufacturing validation, investor planning, and coordinated payer engagement in the 2–6 month window ahead of a potential approval decision.
In‑House Manufacturing & Scale PlanOwning GMP capacity and a defined expansion roadmap reduces dependence on third-party partners, improves supply security for an ultra-cold biologic, and supports planned stockpiling. This structural manufacturing control aids margin capture and operational readiness if approval is achieved, relevant across the next several quarters.
Bears Say
Litigation And Distribution UncertaintyActive litigation over U.S. distribution creates durable uncertainty about commercialization rights, potential injunctions, and timing. A court outcome could force repayment or rework distribution terms, materially delaying launch preparation and complicating partner negotiations and supply plans over months.
Persistent Cash Burn & No Product RevenueSustained operating losses and negative operating/free cash flow are structural financing risks. Although management cites runway into 2027, continued cash burn without product revenue raises refinancing, dilution, or commercialization-risk possibilities that could constrain execution after regulatory outcomes.
Payer/Pricing And Access ComplexityUnresolved ASP/AMP and transfer-pricing complexities create a structural barrier to reimbursement and provider uptake. Even with approval, unclear pricing mechanics could limit access, curtail revenue realization, and force renegotiation of commercial arrangements over the medium term.
Capricor Therapeutics News
CAPR FAQ
What was Capricor Therapeutics, Inc.’s price range in the past 12 months?
Capricor Therapeutics, Inc. lowest stock price was $4.30 and its highest was $40.37 in the past 12 months.
What is Capricor Therapeutics, Inc.’s market cap?
Capricor Therapeutics, Inc.’s market cap is $1.13B.
When is Capricor Therapeutics, Inc.’s upcoming earnings report date?
Capricor Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 24 days.
How were Capricor Therapeutics, Inc.’s earnings last quarter?
Capricor Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of -$0.507 by -$0.083.
Is Capricor Therapeutics, Inc. overvalued?
According to Wall Street analysts Capricor Therapeutics, Inc.’s price is currently Undervalued.
Does Capricor Therapeutics, Inc. pay dividends?
Capricor Therapeutics, Inc. does not currently pay dividends.
What is Capricor Therapeutics, Inc.’s EPS estimate?
Capricor Therapeutics, Inc.’s EPS estimate is -0.59.
How many shares outstanding does Capricor Therapeutics, Inc. have?
Capricor Therapeutics, Inc. has 57,911,892 shares outstanding.
What happened to Capricor Therapeutics, Inc.’s price movement after its last earnings report?
Capricor Therapeutics, Inc. reported an EPS of -$0.59 in its last earnings report, missing expectations of -$0.507. Following the earnings report the stock price went down -3.775%.
Which hedge fund is a major shareholder of Capricor Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CAPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Capricor Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.00 (52.74% Upside)
$53.00 (52.74% Upside)
Blogger Sentiment
Bullish
CAPR Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 149.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 6.1%
Last 30 Days ▲ 6.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
171.50%
12-Months-Change
Fundamentals
Return on Equity
-59.27%
Trailing 12-Months
Asset Growth
112.19%
Trailing 12-Months
Company Description
Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
CAPR Stock 12 Month Forecast
Average Price Target
$53.00
▲(52.74% Upside)
Technical Analysis
Ownership Overview
0.93% Insiders
8.19% Mutual Funds
<0.01% Other Institutional Investors
77.54% Public Companies and
Individual Investors